Aura Biosciences(US:AURA)2023-03-29 15:48Company Overview - Aura Biosciences is developing virus-like drug conjugates (VDCs) to target multiple solid tumor indications, including ocular and bladder cancers[6] - The company highlights a multi-billion-dollar addressable market opportunity with its novel platform to treat multiple solid tumors[6] - Aura Biosciences has a strong cash position with a cash runway to fund operations into 2025[6] Ocular Oncology Program - The company initiated activities for a global Phase 3 trial for Primary Choroidal Melanoma and plans to initiate a Phase 2 trial for Choroidal Metastasis in the second half of 2023[6] - In Primary Choroidal Melanoma, approximately 80% of patients are diagnosed with early-stage disease, representing a significant target population[17] - Current radiotherapy treatments leave approximately 70% of patients with major irreversible vision loss within 5-10 years[26] - Phase 2 interim data showed an 89% tumor control rate in the highest dose/regimen group (3 cycles)[39] and 100% tumor control rate in planned Phase 3 population[46] - Phase 2 interim analysis demonstrated visual acuity preservation in approximately 90% of patients[47] - Phase 2 interim data demonstrated a statistically significant tumor growth rate reduction with a p-value of <0.0001 in the planned Phase 3 population[53] - The company estimates a total addressable market of 33,500 for the Ocular Oncology Franchise, including 20,000 Choroidal Metastasis patients diagnosed each year in the US/EU[70, 71] Urologic Oncology Program - The company is enrolling patients in a Phase 1 trial in Non-Muscle Invasive Bladder Cancer (NMIBC), with initial data expected in the second half of 2023[84] - The company notes that NMIBC has a high incidence globally, affecting over 500,000 patients per year[84]